Pharma Regulatory Summit 2024

7th Annual Pharma Regulatory Summit 2024 is organized by Virtue Insight and will be held on Mar 21, 2024 at Kohinoor Continental, Mumbai, Maharashtra, India.

Description:
The 7th Annual Pharma Regulatory Summit 2024 congregates foremost global pharmaceutical industry professionals and regulators to share their insights on technologies, approaches, and solutions that will drive innovation and quality for the medicines delivered to patients worldwide. This interactional setting with expert-led regulatory and industry presentations, and forums will ensure pharmaceutical industry professionals are expedient to develop and apply ingenious solutions in today’s global regulatory environment.

KEY SPEAKERS:

• MAYUR PARMAR, Drugs Inspector (Deputy Collector, Gujarat Government), FDA
• AMIT PANDEY, Executive Vice President & General Counsel, GSK
• PRABIR KUMAR PAL, Senior Vice President - Quality & Compliance, Alkem Laboratories
• MUKESH KUMAR, Senior VP & Head, Clinical R&D, Cipla
• PRATIK SHAH, Vice President - Medical Affairs, Bharat Serums and Vaccines
• RASHMI HEGDE, Executive Vice President – Medical, GSK
• VIPIN SETHI, AVP, Global Head – PV, Head – Medical Affairs, Cadila
• GEETA SHANBHAG, VP - Pharmacovigilance & Medico-Regulatory Affairs, Ipca Laboratories
• RAHUL GUPTA, Vice President, Regulatory Affairs, USV
• BIJENDER MISHRA, Chief Information Security Officer (CISO), Alkem Laboratories
• YASHMIN SHENOY, Senior Director - Regulatory Affairs, Sanofi
• OMPRAKASH S. SADHWANI, Former Joint Commissioner & Controlling Authority, FDA (Maharashtra State)
• SAILESH YHNB, Associate Director, RA Device Established Products, Novo Nordisk
• KEDAR NAYAK, Head - Clinical Development, GSK
• DEVEN BABRE, Former Director Analytics & Benchmarking, GSK
• HARSHAD KOTHAWADE, Director, Head of Regulatory Management & Trade Compliance India, South East Asia, ANZ, Merck Group
• VAIBHAV SALVI, Director & Head – Clinical Study Unit, India and South East Asia, Sanofi
• PRIYA CHATTERJEE, Head Regulatory Affairs - South Asia, Bayer
• DILIP PAWAR, Global Head - Medical Affairs and Pharmacovigilance, Unichem Laboratories
• POOJA THAKUR, Associate Director, Regulatory Intelligence & Reporting, Advanz Pharma
• MARTINA GOMES, Head, Reg Affairs – CH, Bayer
• AKSHAYA S. ODAK, Head Regulatory Affairs (Biotech), Lupin
• SADANAND KULKARNI, Head- Medical, Regulatory, Vigilance & Quality South Asia, Fresenius Kabi
• MAYUR MAYBHATE, Head Medical Affairs, Alkem Laboratories
• GIRISH SANE, Section Head PV, Macleods Pharmaceuticals
• JEGAN ISRAEL, Head of Quality & Compliance (General Manager), Zydus Group
• SWEETY MATHEW, Regulatory Professional, RA CMC Biotech & Rare Disease, Novo Nordisk
• NEELU GOEL, Regulatory Affairs - Head Business continuity & Compliance, Sun Pharma

Plus more joining soon

KEY THEMES DISCUSSED:

• Current regulatory framework – contemporary developments at a glance - Making the best out of the situation
• Outlining major legal challenges currently faced – Ways to cross these barriers
• ‘One Quality One Standard’ - Proposal for linking State & Central Drug Regulatory bodies for their innovative processes
• RWE / RWD - How it could be used to support regulatory decision-making
• Current regulatory compliance issues & opportunities for regulatory authorities & industry
• Impact of technology - How do digital applications conflict with the legal & regulatory landscape?
• Recent Clinical development - Recent regulatory updates – The new normal
• Remote trials – finally the reality – Regulations
• Overcoming the main challenges of filing variations in India
• "Engaging Patients for Patient Safety", "Elevate the Voice of Patients"
• Evolving Predicaments in Regulations of Medical Devices
• India, An Emerging Pivot for Biosimilars - A detailed glimpse into current streamlines & guidance
• Drug Licensing & advancing approaches – proposal of exclusive bills for drug dealing authority
• Quality audits to ensure compliance with regulatory requirements
• Replacement of the surviving act by The New Drugs, Medical Devices and Cosmetics Bill, 2023
• Overcoming key challenges with product registration in India
• Outlining key requirements for filing variations in India
• Practical guidance for drug registration compliance in India
• Navigating the best regulatory pathway for successful drug approval
• Be part of a major networking opportunity

SPONSORSHIP:
We have more sponsorship opportunities available for both the events, which gives you an opportunity to exhibit/booth/speak and create brand awareness.